Important note: Information in this article was accurate in 2009. The state of the art may have changed since the publication date.
|
|
Sexually Transmitted Diseases Vol. 36; No. 10: 629-636 (10..09) - Tuesday, November 10, 2009
Elizabeth Pultorak; William Wong; Charles Rabins; Supriya D. Mehta
Illinois Department of Public Health data were accessed to estimate the number of incident cases of STIs - chlamydia, gonorrhea, and primary and secondary syphilis - among persons ages 15 to 24, accounting for the proportion of undiagnosed and unreported cases, and sexually active population. STI cost data were obtained from published literature; these were multiplied by the estimated incident cases of STIs in 2005 and 2006 to determine direct medical costs of incident infections. The study's results estimate incident rates per 100,000 population and costs in 2007 US dollars by age, gender, race and county.
The results were reported as follows:
*Chlamydia - Incidence and cost in 2005: 5,030 per 100,000 population, $27,576,686. Incidence and cost in 2006: 5,259 per 100,000 population, $28,779,734.
*Gonorrhea - Incidence and cost in 2005: 1,740 per 100,000 population, $7,698,135. Incidence and cost in 2006: 1,704 per 100,000 population, $7,546,500.
*Syphilis - Incidence and cost in 2005: 9.4 per 100,000 population, $59,940. Incidence and cost in 2006: 10.4 per 100,000 population, $66,333.
Ten counties accounted for more than 80 percent of the estimated statewide morbidity and costs. For all STIs, incidence and costs were highest among women and blacks.
"Estimates of STI incidence and costs are conservative, yet represent a significant economic burden in Illinois," the authors concluded. "Focusing prevention efforts on locales with the highest STI rates may maximize effectiveness in terms of disease prevention and cost reduction."
091110
AD091928
Copyright © 2009 - Information, Inc., Bethesda, MD. The CDC National Center for HIV, STD and TB Prevention provides the following information as a public service only. Providing synopses of key scientific articles and lay media reports on HIV/AIDS, other sexually transmitted diseases and tuberculosis does not constitute CDC endorsement. This daily update also includes information from CDC and other government agencies, such as background on Morbidity and Mortality Weekly Report (MMWR) articles, fact sheets, press releases and announcements. Reproduction of this text is encouraged; however, copies may not be sold, and the CDC HIV/STD/TB Prevention News Update should be cited as the source of the information. Contact the sources of the articles abstracted below for full texts of the articles.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from the Elton John AIDS Foundation, National Library of Medicine, AIDS Walk of Orange County, and donations from users like you.
Always watch for outdated information. This article first appeared in 2009. This material is designed to support, not replace, the relationship that exists between you and your doctor.AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2009. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.
.